Table 2 Patient characteristics in “real-world practice” studies
1st author | Number of patients | Median age (range) | Therapy (%) | Diagnosis | del 11q22.3 (%) | del 17p13.1 (%) | CYP3A45 strong inhibitors | ||
|---|---|---|---|---|---|---|---|---|---|
Front-line | Relapse | CLL (%) | SLL (%) | ||||||
Mato et al. [8] | 197 | 66 (NR) | 19 | 81 | 100 | 0 | NR | NR | Excluded |
Ysebaert et al. [10] (French cohort) | 428 | 70 (33–93) | 2.6 | 97.4 | 100 | 0 | NR | 45.1 | NR |
Winqvist et al. [11] (Swedish cohort) | 95 | 69 (42–86) | 0 | 100 | 98 | 2 | 18 | 63 | Excluded |
Akhtar et al. [16] | 70 | 68.0 (48.4–92.0) | 10 | 90 | 100 | 0 | 24 | 10 | NR |
Mato et al. [13] | 391 | 68 (36–96) | 100 | 0 | 100 | 0 | 17.1 | 29.8 | NR |
Finnes et al. [14] | 118 | 59 (29–83) | 5.9 | 94.1 | 89 | 11 | 13 | 17 | Included |
UK CLL forum [7] | 315 | 69 (42–93) | 0 | 100 | 100 | 0 | NR | 28.3 | NR |
Mato et al. [9] | 616 | 60 (22–95) | 13 | 87 | 100 | 0 | 35 | 26 | NR |
Iskierka-Jażdżewska et al. [17] (Polish cohort) | 165 | 63 (40–84 | 0 | 100 | 97 | 3 | NR | 18.4 | Excluded |
Mato et al. [15] | 178 | 60 (33–89) | 100 | 0 | 100 | 0 | 37 | 37 | Excluded |